VERTIS CV Trial: The SGLT-2 inhibitors are the next generation drugs for type 2 diabetes as well as patients with heart failure. We have seen…
The SGLT-2 inhibitors were initially developed for diabetes but eventually noted to have significant effects on outcomes in patients with heart failure in addition to…
The VICTORIA trial was a randomized controlled trial that tested the use of vericiguat in patients with heart failure with reduced ejection fraction. Vericiguat is…